Autonomous Hyperparathyroidism Following Long-term Phosphate Treatment for Tumor-Induced Osteomalacia: Case Report and Review of the Literature : The Endocrinologist

Journal Logo

CME Review Article #25

Autonomous Hyperparathyroidism Following Long-term Phosphate Treatment for Tumor-Induced Osteomalacia

Case Report and Review of the Literature

Tournis, Symeon MD*; Samdanis, Vasilios MD*; Economopoulos, Dimitrios MD*; Giannikou, Panagiota MD*; Lyritis, George P. MD, PhD

Author Information
The Endocrinologist 17(5):p 263-266, September 2007. | DOI: 10.1097/TEN.0b013e3181514e2b

Abstract

Development of secondary or even tertiary hyperparathyroidism following phosphate administration is an established complication in patients with X-linked hypophosphatemic rickets. However, in tumor-induced osteomalacia (TIO) there are very few documented cases of hyperparathyroidism persisting even after excision of the tumor (tertiary hyperparathyroidism). The development of hyperparathyroidism in TIO is related to long-term phosphate administration, which represents the main treatment option in cases of unlocalized or nonexcisable tumors. Furthermore, low or inappropriately normal calcitriol levels either systemically or at the level of parathyroid cell are probably implicated in parathyroid tumorigenesis. We present a case of a 68-year-old female patient with TIO who received long-term phosphate treatment prior to localization and excision of the tumor and afterward developed autonomous hyperparathyroidism.

© 2007 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Access through Ovid